{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:04:27Z","timestamp":1788923067778,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ygyno.2014.06.025","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T19:00:09Z","timestamp":1404241209000},"page":"591-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma"],"prefix":"10.1016","volume":"134","author":[{"given":"Samantha","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Mosig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Rahaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Prasad-Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Halpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Noel","family":"Billaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dottino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Martignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.06.025_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ygyno.2012.05.038","article-title":"Height, weight, BMI and ovarian cancer survival","volume":"127","author":"Kotsopoulos","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ygyno.2010.01.048","article-title":"Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies","volume":"117","author":"Darcy","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0020","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","article-title":"Ten-year relative survival for epithelial ovarian cancer","volume":"120","author":"Baldwin","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.04.004","article-title":"Treatment of recurrent ovarian cancer relapsing 6\u201312months post platinum-based chemotherapy","volume":"64","author":"Colombo","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0030","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.ejca.2012.04.001","article-title":"Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis","volume":"48","author":"Monk","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fonc.2013.00251","article-title":"Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment","volume":"3","author":"Chien","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2013.08.017","article-title":"Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer","volume":"89","author":"Colombo","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0045","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1054\/bjoc.1999.1053","article-title":"Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial","volume":"82","author":"Windbichler","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2008.01.005","volume":"109","author":"Alberts","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0055","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1002\/ijc.24214","article-title":"Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer","volume":"124","author":"Zeimet","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0060","first-page":"M9","article-title":"IRF-1: the transcription factor linking the interferon response and oncogenesis","volume":"1333","author":"Taniguchi","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/107999002753452610","article-title":"Activities of IRF-1","volume":"22","author":"Kroger","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0070","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ejca.2012.09.024","article-title":"IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness","volume":"49","author":"Pavan","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1757-2215-5-3","article-title":"IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer","volume":"5","author":"Mosig","year":"2012","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0080","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","article-title":"TopHat: discovering splice junctions with RNA-Seq","volume":"25","author":"Trapnell","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nbt.1621","article-title":"Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation","volume":"28","author":"Trapnell","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0090","series-title":"Bioinformatics and computational biology solutions using R and bioconductor limma: linear models for microarray data","author":"Gentleman","year":"2005"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0095","doi-asserted-by":"crossref","first-page":"e17490","DOI":"10.1371\/journal.pone.0017490","article-title":"Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/ERC-11-0329","article-title":"Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients","volume":"19","author":"Gyorffy","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0105","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0110","first-page":"413","article-title":"Primary cytoreductive surgery for epithelial ovarian cancer","volume":"61","author":"Hacker","year":"1983","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2010.02.010","article-title":"Unmasking the complexities of mucinous ovarian carcinoma","volume":"117","author":"Frumovitz","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0120","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1200\/JCO.2007.11.0775","article-title":"Immunologic approaches to ovarian cancer treatment","volume":"25","author":"Sabbatini","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2013.07.105","article-title":"Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma","volume":"131","author":"Chen","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0135","doi-asserted-by":"crossref","first-page":"912102","DOI":"10.4061\/2011\/912102","article-title":"The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer","volume":"2011","author":"Schwartz","year":"2011","journal-title":"Int J Breast Cancer"},{"key":"10.1016\/j.ygyno.2014.06.025_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0092-8674(94)90132-5","article-title":"Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1","volume":"77","author":"Tanaka","year":"1994","journal-title":"Cell"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581401066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581401066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T05:02:48Z","timestamp":1565586168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581401066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S009082581401066X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}